Presented by Cavan Reilly, PhD
Professor, Division of Biostatistics, University of Minnesota
In response to the COVID-19 outbreak, an unprecedented level of scientific effort has been expanded to develop vaccines and therapeutics: here, we focus on therapeutics. Initially, many existing drugs were examined for potential as therapeutic agents. While some of these efforts have been successful, at least in some settings (e.g., remdesivir and dexamethasone), there is still an urgent, unmet need for more effective therapeutics. Over the last year, many companies have developed neutralizing monoclonal antibodies designed specifically for combating COVID-19. Due to the large number of agents, we designed an experimental approach to rapidly identify treatments that are likely to have a substantial impact on COVID-19 outcomes in hospitalized patients. In this presentation, we review the design of this platform trial and provide an update on the current state of treatment of COVID-19 with neutralizing monoclonal antibodies.
Free and open to the public.